Seeking Alpha

Cubist +3.2% AH; FDA accepts Sivextro

  • The FDA has approved Cubist's (CBST) Sivextro for "the treatment of adult acute bacterial skin and skin structure infections."
  • The company states Sivextro is "one of at least four antibiotics Cubist hopes to deliver" by 2020. A European Commission ruling on the drug is expected in 1H15.
  • Shares rose 5.4% in regular trading following news the FDA had granted priority review to an NDA for Cubist's investigational antibiotic ceftolozane/tazobactam"
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs